Skip to main content

Table 1 Baseline characteristics

From: A feasibility randomised controlled trial of Novel Activity Management in severe ASthma-Tailored Exercise (NAMASTE): yoga and mindfulness

  Yoga group Control group p
N 15 9  
Current age in years, mean (SD) 67 (9) 68 (8) 0.86
Female, N (%) 9 (60%) 5 (56%) 0.83
Employed full- or part-time, N (%) 5 (33%) 3 (33%) 1.00
Ex-smoker, N (%) 5 (33%) 3 (33%) 1.00
Age of asthma diagnosis, median (IQR) 11 (3, 48) 40 (22, 45) 0.20
Number of exacerbations in the last 12 months, median (IQR) 2 (1, 4) 3 (2, 3) 0.21
CCI, median (IQR) 0 (0, 4) 0 (0, 2) 0.59
Current medication use
 ICS/LABA, N (%) 15 (100%) 9 (100%) N/A
 ICS Beclomethasone equivalent dose, median (IQR) 2000 (1000, 2000) 2000 (1000, 2000) 0.36
 Biological therapies, N (%) 10 (67%) 7 (78%) 0.56
 LAMA, N (%) 8 (53%) 5 (56%) 0.92
 LTRA, N (%) 0 (0%) 1 (11%) 0.19
 Maintenance oral corticosteroid, N (%) 5 (33%) 2 (22%) 0.56
  1. CCI Charlson Comorbidity Index, ICS inhaled corticosteroid, IQR interquartile range, LABA long-acting beta-agonist, LAMA long-acting muscarinic antagonists, LTRA leukotriene receptor antagonist, N number, N/A not applicable